Scientists test new Cancer-Fighting duo in early trial
NCT ID NCT02298959
Summary
This early-stage study is testing a new combination of two existing cancer drugs, pembrolizumab and ziv-aflibercept, in patients with advanced solid tumors. The main goal is to find the safest and most effective dose of the combination. Researchers will also look for early signs that the treatment can help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT OVARIAN CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BCCA-Vancouver Cancer Centre
Vancouver, British Columbia, V5Z 4E6, Canada
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Moffitt Cancer Center - McKinley Campus
Tampa, Florida, 33612, United States
-
Moffitt Cancer Center-International Plaza
Tampa, Florida, 33607, United States
-
National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Maryland, 20892, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
University Health Network-Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
Conditions
Explore the condition pages connected to this study.